New drug shows promise for rare hormone disorder

NCT ID NCT03257462

Completed Disease control Sponsor: Spruce Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new drug called SPR001 in 24 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The study aimed to see if SPR001 is safe and can improve hormone control. Participants took multiple doses of the drug, and researchers measured changes in key hormones like 17-hydroxyprogesterone. The results could point toward a better way to manage this lifelong condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPR001 capsules
What this could lead to: If successful, SPR001 could offer a new way to better control hormone levels in people with classic congenital adrenal hyperplasia, potentially reducing symptoms and the need for high-dose steroids.
What could go wrong: This is a small, early-phase trial with only 24 participants. The drug may not show enough benefit or could have side effects. More research is needed before it could become a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAH - CONGENITAL ADRENAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAH - CONGENITAL ADRENAL HYPERPLASIA CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Locations

Spruce Biosciences Clinical Site

Orange, California, 92123, United States
Spruce Biosciences Clinical Site

San Diego, California, 92123, United States
Spruce Biosciences Clinical Site

Melbourne, Florida, 32935, United States
Spruce Biosciences Clinical Site

Atlanta, Georgia, 30046, United States
Spruce Biosciences Clinical Site

Indianapolis, Indiana, 46202, United States
Spruce Biosciences Clinical Site

Ann Arbor, Michigan, 48109, United States
Spruce Biosciences Clinical Site

Minneapolis, Minnesota, 55414, United States
Spruce Biosciences Clinical Site

Las Vegas, Nevada, 89148, United States
Spruce Biosciences Clinical Site

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.